A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

NCT00458146 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Merrimack Pharmaceuticals